MédiMabs can produce monoclonal antibodies in ascitic fluid for clients when justified.
Ascitic fluid (or ascites) is the fluid extracted from a peritoneal tumour generated by injecting a hybridoma cell line, secreting the desired antibody, into the primed peritoneal cavity of mice. The hybridoma cells grow into the cavity to high concentration while continuously secreting the antibody.
Production of ascites is very cost-effective, however, according to the Canadian Counsil of Animal Care (CCAC) the production of ascites should be considered only when there are legitimate circumstances for its use and since efficient in vitro methods for large scale production are available, the use of the ascites method should be the exception for scientific justification of ascites production, when:
- The hybridoma cell line will not adapt well to in vitro conditions.
- Some cell lines that do adapt become unable to maintain adequate production of mAb
- mAb from mouse ascitic fluids is essential for experiments in vivo in mice
- Serum-free or low-serum conditions cannot provide sufficient amounts of mAb (such as the evaluation of new vaccines against infectious organisms).
- Culture methods yield populations of IgG mAb that are glycosylated at positions different from those harvested from mouse ascites fluid, thereby influencing antigen-binding capacity and important biologic functions.
- Hybridoma cells producing mAb are contaminated with infectious agents, such as yeasts or fungi, the cells often must be passed through mice.